Allogeneic T-Cell Induction of Endogenous IL-12
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods face challenges in effectively promoting IL-12 production in patients, particularly those with cancer, due to toxicity issues associated with exogenous IL-12 administration and tumor inhibition of IL-12 expression.
Innovation Solution
Administering allogeneic activated T-cells to patients, which induce the production of endogenous IL-12 by the patient's antigen-presenting cells, using various routes such as intradermal, intravenous, or intralesional, to achieve detectable and sustained levels of IL-12 in plasma without significant toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If exogenous IL-12 is administered to patients, then IL-12 levels increase, but toxicity increases significantly
Solution Approach 1:
The patent employs the patient's own antigen-presenting cells to produce endogenous IL-12 internally, rather than administering exogenous IL-12. This self-service approach allows the body to generate the required cytokine levels through its own biological mechanisms, avoiding the toxicity associated with external administration while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses antigen-presenting cells as an intermediary between the administered composition and IL-12 production. These cells process the administered material and convert it into endogenous IL-12 through natural biological processes, serving as a mediator that transforms the input into the desired therapeutic output without direct toxic exposure
2Reliability
If immunotherapy is used to promote IL-12 production, then anti-tumor immunity is enhanced, but tumor inhibition of IL-12 expression persists
Solution Approach 1:
The patent administers a composition containing antigens and adjuvants before attempting to stimulate IL-12 production. This preliminary action prepares the antigen-presenting cells and creates a favorable immunological environment that overcomes the tumor's suppressive effects, enabling subsequent successful IL-12 induction
Solution Approach 2:
The patent employs adjuvants in the administered composition that counteract the tumor's inhibitory effects on IL-12 expression. These adjuvants create a preliminary opposing force against the tumor's suppression mechanisms, neutralizing the harmful inhibition before it can block IL-12 production
3Quantity of substance
If allogeneic activated T-cells are administered, then endogenous IL-12 production is induced, but treatment complexity increases
Solution Approach 1:
The patent uses allogeneic activated T-cells that can serve multiple functions: they act as antigen-presenting cells, produce cytokines, and stimulate endogenous IL-12 production. This multi-functionality reduces the need for separate treatment components, simplifying the overall treatment approach despite the sophisticated biological mechanisms involved
Data Source
AI summary
The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.